Hexarelin
Tissue & recoveryAlso known as Examorelin
Evidence tier
Substantial published literature
312 publications over 32 years · trials not yet curated
- Researched since
- 1994
- Publications
- 312
- Mean purity
- 99.1%
- Vendors listing
- 5
Modern Aminos shows the highest mean assayed purity for Hexarelin at 99.1% across 1 lot record. Purity figures below come from the certificates named in each row.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1994 — 32 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
312 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.1% across 1 certificate
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
single lot on record, mean label deviation 0.0%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
5 of 5 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
1 of 1 certificate from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Hexarelin?
A synthetic growth-hormone-releasing hexapeptide studied for growth hormone secretion and cardiovascular effects.
Studied in published research for growth-hormone release and cardiovascular effects.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Studied in animal models and human growth-hormone research. PepIndex does not evaluate clinical significance and does not describe administration.
- The cardiovascular action of hexarelin — Journal of geriatric cardiology : JGC (2014)
Peer-reviewed article indexed in PubMed, published in Journal of geriatric cardiology : JGC (2014).
- Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway — European journal of medical research (2023)
Peer-reviewed article indexed in PubMed, published in European journal of medical research (2023).
- Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation — Microvascular research (2022)
Peer-reviewed article indexed in PubMed, published in Microvascular research (2022).
- Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases — Endocrine (2015)
Peer-reviewed article indexed in PubMed, published in Endocrine (2015).
- Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury — Drug target insights (2021)
Peer-reviewed article indexed in PubMed, published in Drug target insights (2021).
- Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats — Canadian journal of physiology and pharmacology (2021)
Peer-reviewed article indexed in PubMed, published in Canadian journal of physiology and pharmacology (2021).
- Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy — Die Pharmazie (2019)
Peer-reviewed article indexed in PubMed, published in Die Pharmazie (2019).
- Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE(-/-) mice — Peptides (2019)
Peer-reviewed article indexed in PubMed, published in Peptides (2019).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| Northline LabsISO/IEC 17025 | 91.293% | $9.00 (71%) | 0 | — | — | |
| Good Science Bio | 79.275% | $7.00 (55%) | 0 | — | — | |
| Protide Health | 75.194% | $18.33 (144%) | 0 | — | — | |
| Modern AminosISO/IEC 17025 | 74100% | — | 1 | 99.1% | 0.0% | |
| GenX Peptides | 62.268% | $16.50 (129%) | 0 | — | — |
Certificate records
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Source |
|---|---|---|---|---|---|---|---|---|
| Modern Aminos | BX-P-TIC8 | Freedom Diagnostics | 7.5 mg | 7.5 mg | 0.0% | 99.1% | Vendor-published |